Concepedia

Markus Warmuth

MW

52

Publications

17.6K

Citations

40

H-Index

1996

Active since

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Novartis (Switzerland)

Dana-Farber Cancer Institute

Novartis Institutes for BioMedical Research

Novartis (United States)

Markus Warmuth is an author at Genomics Institute of the Novartis Research Foundation specializing in medicine, tumor biology, and cell biology.

Top concepts

MedicineCell BiologyTumor BiologyCancer ResearchPharmacologyCell SignalingDrug DiscoveryRadiation OncologyOncologyCancer Biology

Publications per year

1996–2025

52

Publications

52

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.3K citations

Tumor Biology, Predictive Modelling, Drug Target +12

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Ying-Nan P. Chen, Matthew J. LaMarche, Ho Man Chan et al. · Nature · 2016 · 893 citations

Cancer Research, Allosteric Inhibition, Signal Transduction +12

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Silvia Buonamici, Juliet Williams, Michael Morrissey et al. · Science Translational Medicine · 2010 · 553 citations

Rows per page

1–5 of 52